Little attention was given to the interaction between tumor and stromal cells in urothelial bladder carcinoma (UBC). While recent studies point towards the existence of different fibroblast subsets, no comprehensive analyses linking different fibroblast markers to UBC patient survival have been performed so far. Through immunohistochemical analysis of five selected fibroblast markers, namely alpha smooth muscle actin (ASMA), CD90/Thy-1, fibroblast activation protein (FAP), platelet derived growth factor receptor-alpha and-beta (PDGFRa,-b), this study investigates their association with survival and histopathological characteristics in a cohort of 344 UBC patients, involving both, muscleinvasive and non-muscle-invasive cases. The data indicates that combinations of stromal markers are more suited to identify prognostic patient subgroups than single marker analysis. Refined stromamarker-based patient stratification was achieved through cluster analysis and identified a FAPdominant patient cluster as independent marker for shorter 5-year-survival (HR(95% CI)2.25(1.08-4.67), p = 0.030). Analyses of interactions between fibroblast and CD8a-status identified a potential minority of cases with CD90-defined stroma and high CD8a infiltration showing a good prognosis of more than 80% 5-year-survival. Presented analyses point towards the existence of different stroma-cell subgroups with distinct tumor-modulatory properties and motivate further studies aiming to better understand the molecular tumor-stroma crosstalk in UBC. The estimated incidence of urinary bladder cancer (UBC) worldwide was about 550.000 new cases and 200.000 deaths in 2018 1 , with highest incidences indicated in developed areas 2. Given that the prevalence of UBC is several times higher than the incidence, it represents a major burden for health care systems. Carcinomas originating from the urothelium, the inner surface of the bladder, represent the most common type of bladder cancer 3,4. Approximately 70% of all newly diagnosed cases are classified as non-muscle-invasive bladder cancer disease, while about 30% of patients have already muscle-invasive tumors with 10-15% of them being metastatic 5-8. Reported 5-year recurrence rates of non-muscle invasive cases range between 40-70% among the highest recurrence rates of solid tumors 3,9. Multidisciplinary approaches have been established in order to improve patient management and to decrease the mortality rate, but still treatment strategies for UBC remain controversial. A better understanding of the mechanisms underlying tumor progression is crucial and novel prognostic and predictive markers as well as therapeutic targets need to be identified 10,11. Recent research efforts on UBC aimed mostly to decipher molecular drivers of an invasive tumor phenotype through description of genetic varieties, and with the introduction of checkpoint inhibitory immunotherapy, awareness has also risen for tumor infiltrating leukocytes 12,13. However, little attention was given the interaction of tumor cells and non-leukoc...